CA2319492A1 - Agents de dimerisation, production et utilisation - Google Patents

Agents de dimerisation, production et utilisation Download PDF

Info

Publication number
CA2319492A1
CA2319492A1 CA002319492A CA2319492A CA2319492A1 CA 2319492 A1 CA2319492 A1 CA 2319492A1 CA 002319492 A CA002319492 A CA 002319492A CA 2319492 A CA2319492 A CA 2319492A CA 2319492 A1 CA2319492 A1 CA 2319492A1
Authority
CA
Canada
Prior art keywords
cells
domain
fkbp
rapalog
frb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002319492A
Other languages
English (en)
Inventor
Stuart L. Schreiber
Gerald R. Crabtree
Stephen D. Liberles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2319492A1 publication Critical patent/CA2319492A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des agents et des procédés permettant de réguler un certain nombre d'événements biologiques, comme la transcription et la croissance de gènes cibles, ou la prolifération et la différenciation de cellules manipulées.
CA002319492A 1998-02-13 1999-02-12 Agents de dimerisation, production et utilisation Abandoned CA2319492A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7458498P 1998-02-13 1998-02-13
US60/074,584 1998-02-13
PCT/US1999/003095 WO1999041258A1 (fr) 1998-02-13 1999-02-12 Agents de dimerisation, production et utilisation

Publications (1)

Publication Number Publication Date
CA2319492A1 true CA2319492A1 (fr) 1999-08-19

Family

ID=22120362

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002319492A Abandoned CA2319492A1 (fr) 1998-02-13 1999-02-12 Agents de dimerisation, production et utilisation

Country Status (5)

Country Link
EP (1) EP1053241A1 (fr)
JP (1) JP2002503667A (fr)
AU (1) AU766513B2 (fr)
CA (1) CA2319492A1 (fr)
WO (1) WO1999041258A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924483D0 (en) * 1999-10-15 1999-12-15 Plant Bioscience Ltd Modified resistance genes
US20030165873A1 (en) 2001-03-02 2003-09-04 Come Jon H. Three hybrid assay system
SG183929A1 (en) 2010-03-29 2012-10-30 Univ Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
EP3699286A1 (fr) 2011-04-20 2020-08-26 The Trustees of the University of Pennsylvania Régimes et compositions pour l'immunisation passive médiée par aav contre des agents pathogènes en suspension dans l'air
JP6170999B2 (ja) * 2012-03-13 2017-07-26 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスおよび化学二量体を用いる選択細胞の標的化
US10634668B2 (en) 2012-09-13 2020-04-28 Takara Bio Usa, Inc. Modifiable chemical inducers of proximity and methods of using the same
WO2014145252A2 (fr) 2013-03-15 2014-09-18 Milone Michael C Ciblage de cellules cytotoxiques par des récepteurs chimériques pour une immunothérapie adoptive
WO2015012924A2 (fr) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Cassettes d'expression préférentielle pour tissus modifiées par un codon, vecteurs les contenant, et utilisation
CN105283553B (zh) 2013-06-11 2021-06-25 克隆技术实验室有限公司 蛋白质富集的微泡及其制备和使用方法
US10196444B2 (en) 2013-07-29 2019-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
WO2015090229A1 (fr) 2013-12-20 2015-06-25 Novartis Ag Récepteur d'antigène chimérique régulable
US10533016B2 (en) 2015-01-09 2020-01-14 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
EA201792500A1 (ru) 2015-05-13 2018-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Aav-опосредованная экспрессия антител против гриппа и способы их использования
EP3368054A4 (fr) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. Expression régulable au moyen d'un virus adéno-associé (vaa)
CN108713028B (zh) * 2016-02-04 2021-12-28 约翰霍普金斯大学 rapafucin文库的合成和组合物
JP7046828B2 (ja) 2016-04-15 2022-04-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 滲出型加齢性黄斑変性の治療のための組成物
SG10201913833PA (en) 2017-02-28 2020-03-30 Univ Pennsylvania Influenza vaccines based on aav vectors
SI3589730T1 (sl) 2017-02-28 2024-04-30 The Trustees Of The University Of Pennsylvania Adeno-povezan virus (AAV) clade F vektor in njihova uporaba
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
WO2018187401A1 (fr) * 2017-04-05 2018-10-11 Warp Drive Bio, Inc. Composés participant à une liaison coopérative et utilisations associées
MX2020003888A (es) 2017-10-18 2020-11-06 Regenxbio Inc Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
MX2020003945A (es) 2017-10-18 2020-11-09 Regenxbio Inc Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .
CA3084551A1 (fr) 2017-12-14 2019-06-20 Bluebird Bio, Inc. Recepteurs de l'interleukine darique
AU2020253462A1 (en) 2019-04-03 2021-10-28 Regenxbio Inc. Gene therapy for eye pathologies
TW202106708A (zh) 2019-04-24 2021-02-16 美商銳進科斯生物股份有限公司 全人類轉譯後修飾之抗體治療劑
AU2020267349A1 (en) 2019-05-04 2021-11-11 Inhibrx Biosciences, Inc. CLEC12a-binding polypeptides and uses thereof
AU2020336314A1 (en) 2019-08-26 2022-04-07 Regenxbio Inc. Treatment of diabetic retinopathy with fully-human post-translationally modified anti-VEGF Fab
WO2021071835A1 (fr) 2019-10-07 2021-04-15 Regenxbio Inc. Composition pharmaceutique de vecteur de virus adéno-associé et méthodes
WO2022060916A1 (fr) 2020-09-15 2022-03-24 Regenxbio Inc. Anticorps vectorisés pour thérapie antivirale
WO2022060915A1 (fr) 2020-09-15 2022-03-24 Regenxbio Inc. Lanadelumab vectorisé et administration de celui-ci
EP4225926A1 (fr) 2020-10-07 2023-08-16 RegenxBio Inc. Thérapie génique pour manifestations oculaires de maladie cln2
AU2021371307A1 (en) 2020-10-28 2023-06-01 Regenxbio, Inc. VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
WO2022094157A1 (fr) 2020-10-28 2022-05-05 Regenxbio Inc. Anticorps vectorisés anti-cgrp et anti-récepteur de cgrp et leur administration
US20230390418A1 (en) 2020-10-29 2023-12-07 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof
AU2021369833A1 (en) 2020-10-29 2023-06-08 Regenxbio Inc. Vectorized tnf-alpha antagonists for ocular indications
IL303236A (en) 2020-12-01 2023-07-01 Univ Pennsylvania New compounds with specific tissue-targeting motifs and preparations containing them
MX2023012513A (es) 2021-04-23 2023-12-15 Univ Pennsylvania Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen.
EP4409010A1 (fr) 2021-10-02 2024-08-07 The Trustees of The University of Pennsylvania Nouvelles capsides de vaa et compositions les contenant
AU2023211652A1 (en) 2022-01-25 2024-08-08 The Trustees Of The University Of Pennsylvania Aav capsids for improved heart transduction and detargeting of liver
WO2023201308A1 (fr) 2022-04-14 2023-10-19 Regenxbio Inc. Thérapie génique pour le traitement d'une maladie oculaire
WO2023205610A2 (fr) 2022-04-18 2023-10-26 Regenxbio Inc. Capsides aav hybrides
AR129215A1 (es) 2022-05-03 2024-07-31 Regenxbio Inc Anticuerpos anti-complemento y agentes del complemento vectorizados y administración de estos
WO2023215807A1 (fr) 2022-05-03 2023-11-09 Regenxbio Inc. INHIBITEURS VECTORISÉS ANTI-TNF-α POUR INDICATIONS OCULAIRES
WO2024073669A1 (fr) 2022-09-30 2024-04-04 Regenxbio Inc. Traitement de maladies oculaires avec des vecteurs viraux recombinés codant un fab anti-vegf
WO2024130067A2 (fr) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Vecteurs mutants aav recombinants avec motifs de ciblage spécifiques des muscles cardiaque et squelettique et compositions les contenant
WO2024130070A2 (fr) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Capsides aav recombinantes avec motifs de ciblage spécifiques du muscle cardiaque et squelettique et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302016D0 (en) * 1993-02-02 1993-03-17 Sandoz Ltd Compounds
WO1997031898A1 (fr) * 1996-02-28 1997-09-04 Ariad Gene Therapeutics, Inc. Derives synthetiques de rapamycine utilises comme agents de multimerisation de proteines chimeres a domaines derives de l'immunophiline

Also Published As

Publication number Publication date
WO1999041258A1 (fr) 1999-08-19
AU766513B2 (en) 2003-10-16
EP1053241A1 (fr) 2000-11-22
JP2002503667A (ja) 2002-02-05
AU2676099A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
AU766513B2 (en) Novel dimerizing agents, their production and use
US6984635B1 (en) Dimerizing agents, their production and use
US7196192B2 (en) 28-epirapalogs
US7067526B1 (en) 28-epirapalogs
US6187757B1 (en) Regulation of biological events using novel compounds
AU755784B2 (en) Regulation of biological events using multimeric chimeric proteins
US6506379B1 (en) Intramuscular delivery of recombinant AAV
WO1996041865A1 (fr) Regulation d'evenements biologiques fondee sur la rapamycine
US7109317B1 (en) FK506-based regulation of biological events
US6566073B1 (en) Materials and methods involving conditional retention domains
AU714904C (en) Rapamcycin-based regulation of biological events
US20030206891A1 (en) Rapamycin-based biological regulation
AU1603900A (en) Fk506-based regulation of biological events
AU1121000A (en) Materials and methods involving conditional retention domains
EP0833894B1 (fr) Regulation d'evenements biologiques fondee sur la rapamycine
AU1121100A (en) Materials and methods involving conditional aggregation domains

Legal Events

Date Code Title Description
FZDE Dead